To examine the role of early carbohydrate recognition/trimming reactions in targeting endoplasmic reticulum (ER)-retained, misfolded glycoproteins for ER-associated degradation (ERAD), we have stably expressed the cog thyroglobulin (Tg) mutant cDNA in CHO cells. We find that inhibitors of ER mannosidase I (but not other glycosidases) acutely suppress cog Tg degradation and also perturb the ERAD process for Tg reduced with dithiothreitol as well as carboxylation-deficient protein C expressed in (warfarin-treated) BHK cells. Kifunensine inhibition of ER mannosidase I also suppresses ERAD in castanospermine-treated cells; thus, suppression of ERAD does not require lectin-like binding of ER chaperones calnexin and calreticulin to monoglucosylated oligosaccharides. Notably, the undegraded protein fraction remains completely microsomeassociated. From pulse-chase studies, kifunensine-sensitive degradation is still inhibitable even one hour after Tg synthesis. Intriguingly, chronic treatment with kifunensine caused a threefold accumulation of cog Tg in CHO cells and did not lead to significant induction of the ER unfolded protein response. We hypothesize that, in a manner not requiring lectin-like activity of calnexin/calreticulin, the recognition or processing of a specific branched N-linked mannose structure enhances the efficiency of glycoprotein retrotranslocation from the ER lumen.
Summary
To examine the role of early carbohydrate recognition/trimming reactions in targeting endoplasmic reticulum (ER)-retained, misfolded glycoproteins for ER-associated degradation (ERAD), we have stably expressed the cog thyroglobulin (Tg) mutant cDNA in CHO cells. We find that inhibitors of ER mannosidase I (but not other glycosidases) acutely suppress cog Tg degradation and also perturb the ERAD process for Tg reduced with dithiothreitol as well as carboxylation-deficient protein C expressed in (warfarin-treated) BHK cells. Kifunensine inhibition of ER mannosidase I also suppresses ERAD in castanospermine-treated cells; thus, suppression of ERAD does not require lectin-like binding of ER chaperones calnexin and calreticulin to monoglucosylated oligosaccharides. Notably, the undegraded protein fraction remains completely microsomeassociated. From pulse-chase studies, kifunensine-sensitive degradation is still inhibitable even one hour after Tg synthesis. Intriguingly, chronic treatment with kifunensine caused a threefold accumulation of cog Tg in CHO cells and did not lead to significant induction of the ER unfolded protein response. We hypothesize that, in a manner not requiring lectin-like activity of calnexin/calreticulin, the recognition or processing of a specific branched N-linked mannose structure enhances the efficiency of glycoprotein retrotranslocation from the ER lumen.
Whether genetic or acquired, ER storage diseases (ERSDs) begin with the synthesis of misfolded versions of exportable proteins within the ER compartment (1) . Generally, these proteins are retained in the endoplasmic reticulum (ER) (2) pending targeting for ER-associated degradation [ERAD, (3) ], at which point they are retrotranslocated to the cytosol (4; 5) and degraded via the ubiquitin-proteasome pathway (6) (7) (8) . For many secretory proteins, the misfolded versions may enter the ER lumen completely before a final cellular disposition is made (9) (10) (11) . Thus, it is not surprising that molecular chaperones acting in the ER lumen have been implicated as participants in the retention and ERAD processes. Of the ER chaperones proposed to function in targeting for retrotranslocation and ERAD, calnexin has been the most often implicated (12) (13) (14) (15) (16) (17) . Other studies, however, have suggested that ERAD is independent of calnexin or that association with calnexin actually prevents ERAD (18) (19) (20) (21) (22) (23) (24) .
The binding of calnexin (and calreticulin) to most exportable substrates occurs via a lectin interaction that requires exposure of monoglucosylated oligosaccharide side chains (25; 26) . In normal mammalian cells, this association is prevented by pre-treatment with castanospermine (CAS), an inhibitor of glucosidases I and II (21; 27; 28) . By contrast, the calnexin interaction is enhanced in cells pre-treated with 1-deoxymannojirimicin (DMM), the general alpha mannosidase inhibitor that prevents the formation of Man [5] [6] [7] glycans which are less efficient substrates for monoglucosylation (29; 30) and may exhibit diminished calnexin binding affinity (31) . Using these inhibitors as well as other approaches, several groups have begun to explore the role of early carbohydrate trimming reactions in the targeting of ER-retained glycoproteins for the ERAD process.
In particular, reports indicate that for yeast preproalpha factor expressed in mammalian cells (32) , the Hong Kong null form of α1-antitrypsin (33), or the δ subunit of the T cell antigen receptor (34) , treatment of cells with DMM results in marked inhibition of the ERAD process. In detailed studies of the Hong Kong null form of α1-antitrypsin, when ERAD was inhibited by cycloheximide treatment, calnexin dissociation and post-translational oligosaccharide trimming were blocked; by contrast, when ERAD was inhibited by DMM, the fraction of antitrypsin dissociated from calnexin appeared normal while mannose trimming was nevertheless blocked (33) . One simple interpretation of these data might be that ERAD proceeds by a pathway (blocked at different points by different inhibitors) that may involve calnexin dissociation followed by additional steps that include trimming to Man 8 . In such a case, the ultimate targeting for retrotranslocation might be 4 reported to result in an ERAD process for mutant antitrypsin that cannot be inhibited by DMM (33) [nor even the proteasome inhibitor lactacystin (35) ]. This has led to an hypothesis that rebinding to calnexin might be an essential step for targeting misfolded N-linked glycoproteins for proteasomal proteolysis.
To test this hypothesis, we have now examined cell culture expression of the cog thyroglobulin mutant (cog Tg, a Leu2263Pro substitution in Tg that causes congenital goiter in homozygous mice) and γ-carboxylation-deficient protein C (cdPC), two misfolded glycoproteins that serve as models of genetic and acquired ERSDs, respectively (36; 37). Like for mutant antitrypsin (38) , ERAD of both proteins is significantly impaired upon specific inhibition of ER mannosidase I. However, in cells pretreated with CAS so that lectin-like binding of calnexin is blocked, the ERAD process is still proteasomal; moreover, it is still largely blocked upon inhibition of ER mannosidase I. While the data do not exclude enhanced calnexin binding under specified experimental circumstances, they signify a more general role for recognition and trimming of specific N-linked mannose residues in the ERAD process for at least a subset of glycoproteins. Oxford GlycoSciences (Abingdon, UK), respectively. Endoglycosidase H was from New England Biolabs (Beverly MA). A polyclonal rabbit antiserum against rat Tg was from Dr. P. R. Larsen (Brigham and Women's Hospital, Boston MA). A polyclonal antiserum against human protein C was developed as described previously (37) . Polyclonal antisera to BiP, calnexin, ERp72, calreticulin, and GRP94 were kindly provided by Dr. P. Kim CHO cells were transfected using calcium phosphate precipitation. Transfectants were selected by growth in G418, and clonal expression of Tg was screened for using 35 S-labeling followed by Tg immunoprecipitation. The stably-transfected BHK cells expressing PC have been described previously (37) . medium. In this case, when the cells were treated with labeling media containing a drug, the media was changed each day, and the same was done for control samples. At the end of each experiment, media was collected and cells were lysed in 0.1% SDS/1% NP-40 plus an anti-protease cocktail (39) . Samples were immunoprecipitated using rabbit anti-rat Tg or anti-human PC antisera followed by 30 ul of Zysorbin. After washing, the immunoprecipitates were dissociated by heating in SDS gel sample buffer. After SDS-PAGE, radioactive band intensity was measured using a Storm 850 phosphorimager (Molecular Dynamics). In some instances, autoradiographic exposures were made using Kodak XAR films at -80 °C.
Experimental Procedures

Materials-
Microsomal sedimentation assay -CHO cells expressing cog Tg in 35 mm dish were pulse-labeled and chased for 6 h. Then, cells were scraped into 400 ul of 50 mM Hepes buffer, pH 7.4, containing 0.25 M sucrose and protease inhibitors, and homogenized by 15 passages through a 27 gauge needle. Nuclei and unbroken cells were removed by centrifugation at 1,100 x g for 10 min, and post-nuclear supernates were further centrifuged at 50,000 rpm for 1 h in a Beckman TL-100 centrifuge. Precipitates (representing the microsomal fraction) and supernates (representing the cytosol fraction) were analyzed by immunoprecipitation, SDS-PAGE, and phosphorimaging.
Results
Degradation of cog Tg by CHO cells -To further explore the ERAD process, we stably
expressed the cog Tg cDNA, which encodes a Leu2263Pro mouse Tg mutant, in CHO cells. As in COS cells (36) , the cog Tg protein was not secreted into the medium (Fig. 1A) . Instead, after a 30 minute pulse labeling with 35 S-amino acids, following a lag time of ~2h during which no degradation was apparent, newly-synthesized cog Tg thereafter was degraded with a subsequent half-time of 2-3 h (Fig. 1B) . Based on this, recovery of cog Tg at the 1h chase time was generally taken as a reference point for most subsequent experiments. At all chase times, the undegraded intracellular Tg remaining was sensitive to digestion with endoglycosidase H (not shown). Notably, the degradation was blocked by ALLN and more specifically, by LLL (MG-132) and lactacystin, indicating a fate of proteasomal proteolysis (Fig. 2) . Thus, cog Tg degradation in CHO cells displayed the classic hallmarks of ERAD (3). Moreover, in initial studies (not shown), we found that, in common with several other N-linked glycoproteins, degradation of newly-synthesized cog Tg was inhibited by DMM (32) (33) (34) . For these reasons, we examined kifunensine (KIF), a specific inhibitor of mannosidase I activity (40) Thus, the data strongly indicate that after KIF treatment, cog Tg protected from ERAD has failed to undergo trimming from Man 9 to Man 8 .
Neither KIF alone nor KIF + CAS treatments were toxic to CHO cells, as neither treatment prevented the secretory trafficking of nonmutant Tg (Fig. 5) . Moreover, following CAS treatment in the presence or absence of KIF, co-precipitation of cog Tg with calnexin was undetectable (not shown). It has been demonstrated for mutant α1-antitrypsin that enhanced calnexin binding to monoglucosylated Man 9 oligosaccharides occurs following postpulse protein synthesis inhibition with cycloheximide, and this correlates with protection from ERAD (33) . While cycloheximide (20 uM) treatment also had a stabilizing effect on cog Tg, this effect was quite modest and tended to be limited to early chase times (see Fig. 8 , below). Taken together, these data suggest that for cog Tg, the lectin-like binding of calnexin is not a major determinant for ERAD, and KIF inhibits a calnexin-independent step in targeting the misfolded glycoprotein for proteasomal degradation.
Undegraded cog Tg is not liberated into the free cytosol -Wiertz et al have suggested that
oligosaccharide processing may occur in the cytosol at a step preceding proteasomal proteolysis, as evidenced by the fact that lactacystin treatment leads to accumulation of an undegraded cytosolic intermediate that can be detected in soluble supernatant after microsomal sedimentation (43) . We therefore performed similar experiments at several chase times for cog Tg in control CHO cells or in cells treated with lactacystin, CAS, or CAS + KIF. As shown in Fig. 6 , lactacystin and CAS + KIF treatments led to cog Tg stability (cell lysate panels). However, at no time could any detectable cog Tg intermediate be found liberated into the free cytosol fraction. In additional trypsin protection experiments (not shown), we found that cog Tg and wild-type Tg were equally protected in microsomal fractions. Moreover, following the protocol described by Johnston et al.
(44), we did not detect the presence of insoluble complexes (aggresomes) of newly-synthesized cog Tg accumulated after 10 h of chase in the presence of proteasomal inhibition (Fig. 7) . Thus, it appears that a bottleneck for cog Tg degradation occurs at or prior to the retrotranslocation process (see Discussion).
Generality of kifunensine Effects -So far, reports of kifunensine inhibtion of ERAD are limited to just a few glycoproteins, such as a C-terminally truncated version of α1-antitrypsin (35) which contains a primary structural defect confined to a discrete protein domain. By contrast, treatment of cells with DTT at low doses (≤ 1 mM) prevents the formation of nascent disulfide bonds (45) and produces massive misfolding of Tg by preventing formation of many of the 60 intrachain disulfide linkages spanning much of the polypeptide (46) . In CHO cells treated with 600 uM DTT, cog Tg was reduced (Fig. 8B) and during an 8h chase was degraded to at least the same extent as in untreated cells (Fig. 8A) . While postpulse protein synthesis inhibition provided no suppression of ERAD under reducing conditions, KIF treatment effectively blocked the degradation of misfolded Tg (Fig. 8A, lower 4 
panels).
To gain an independent assessment of the effect of mannosidase inhibition on ERAD, we examined recombinant protein C expressed in BHK cells. γ-Glutamyl carboxylation is a posttranslational modification that promotes proper folding of protein C and other vitamin K dependent clotting factors in the ER, whereas warfarin inhibition of γ-carboxylation results in misfolding and degradation of carboxylation-deficient protein C (cdPC) (37) via a proteasomal mechanism (47).
Like for cog Tg, a block in glucosidase activity (by CAS) did not stabilize the misfolded glycoprotein, but cdPC was significantly stabilized in cells treated with DMM (not shown), and more specifically, with KIF ( Fig. 9) . KIF-mediated suppression of ERAD was also observed in CAS-treated BHK cells, indicating -like for cog Tg -a dominant effect of the mannosidase I inhibitor (Fig. 9) . Essentially identical observations were made in stably transfected CHO cells expressing protein C (not shown).
In cells treated with tunicamycin, unglycosylated cog Tg and cdPC misfold and are degraded intracellularly with severely impaired anterograde transport through the secretory pathway (48; 49).
However, as shown in Fig. 10 , treatment with KIF has no protective effect on the intracellular degradation of these unglycosylated secretory proteins. These data are consistent with the hypothesis that KIF-mediated suppression of degradation is selective for glycoprotein substrates.
Mannosidase I processing is a relatively slow step in the ERAD pathway -It has been argued that since degradation intermediates do not routinely accumulate in the cytosol during ERAD, steps leading to retrotranslocation are likely to be rate limiting for proteolytic cleavage (50) .
Although it is not clear if ER mannosidase I activity is rate limiting in glycoprotein degradation, we note that KIF addition to CHO cells stabilized cog Tg even when added an hour after synthesis of the mutant glycoprotein (Fig. 11) , at a time before any loss of cog Tg could yet be detected (Fig.   1B) . Protection from ERAD after delayed KIF addition suggested that for a significant fraction of cog Tg molecules, the KIF-inhibitable step had not yet occurred even an hour after synthesis.
Similar protection from ERAD was obtained by delayed KIF addition in cells pre-treated with CAS (not shown).
In 10 uM warfarin-treated BHK cells, cdPC was degraded with a half-time of ~2.5h (Fig. 12) .
When DMM was added up to 1h after pulse-labeling, suppression of ERAD approached that observed in cells pretreated with the mannosidase inhibitor (Fig. 13) . Thus, similar to cog Tg, the step in the ERAD pathway blocked by mannosidase inhibition had not yet occurred for most molecules even an hour after synthesis. Longer chase times prior to DMM addition led to a declining ability to suppress ERAD (Fig. 13) . Similar results were obtained with KIF treatment (not shown). These results suggest that mannosidase I processing is a relatively slow step after misfolded glycoprotein synthesis. We note that even when DMM was used in pretreatment and throughout the chase, some degradation of cdPC still occurred (see Discussion).
Chronic Mannosidase I Inhibition Causes ER accumulation of cog Tg -Since acute KIF treatment caused a profound slowing of glycoprotein ERAD, we predicted that the misfolded protein would begin to accumulate in the ER. Therefore, normal CHO cells or CHO cells expressing cog Tg were treated for 3 d with KIF (which was added to the medium each day). During this period, the cells were labeled continuously with 35 S-amino acids at a constant low specific radioactivity. At the end of the treatment period, cells were examined by specific immunoprecipitation for their levels of Tg and a number of ER resident proteins. As shown in Fig.   14A , after daily addition of KIF for 3 d, cog Tg showed some accumulation in the stably transfected CHO cells, and all of the accumulated Tg was sensitive to digestion with endoglycosidase H (not shown). Interestingly, quantitation showed that cog Tg abundance after chronic KIF treatment rosẽ 3-fold. In control CHO cells, chronic KIF treatment itself had no significant effect on the levels of any of the ER resident proteins measured (Fig. 14A, left 2 lanes) ; more importantly in stably transfected CHO cells, the accumulation of misfolded cog Tg accompanying chronic KIF treatment also did not lead to a significant elevation of ER resident proteins (Fig. 14A, right 2 lanes) . Similar results were obtained by routine Western blotting (not shown). When pulse-chase experiments were performed to examine the fate of newly-synthesized cog Tg after 16 h in cells chronically treated daily with KIF for 3 d (Fig. 14B) , a small (≤ 20%) increase in Tg degradation was observed, which involved proteasomal degradation as it was still sensitive to lactacystin (Fig. 14C) . Together, the data raise the possibility of some form of adaptation to chronic mannosidase I inhibition which is associated with only modest steady-state accumulation of misfolded Tg that does not elevate ER chaperone levels. Studies in S. cerevisiae brought forward the suggestion that calnexin might facilitate retrotranslocation to the cytosol (14) . It should be noted, however, this observation was made for unglycosylated proalpha-factor for which it is unclear how the lectin-only model of calnexin activity (25; 26) would apply. At the same time cells devoid of Mns1p (ER mannosidase I) were found to exhibit abnormally diminished degradation of a mutant form of carboxypeptidase y (52); these results have recently been confirmed and extended to show that such degradation does not require the formation of glucosylated oligosaccharides (53) . Taken together, these findings in S.
cerevisiae indicate suppressive effects of ERAD as a consequence of decreased ER mannosidase I activity without an evident requirement for the lectin-like activity of calnexin.
Since the role of calnexin in S. cerevisiae may be unique to that organism (54), it is of interest to know how the foregoing reports compare to the situation for glycoprotein ERAD in higher eukaryotes. Specifically, while several groups have now found that inhibition of ER mannosidase activity can also suppress ERAD in mammalian cells (24; 32-34; 38) , study of a C-terminally truncated α1-antitrypsin expressed in mouse hepatoma cells led to the recent suggestion that ER mannosidase I specifically targets misfolded glycoproteins for disposal using a lectin-mediated process dependent upon binding monoglucosylated Man 8 oligosaccharides to calnexin (35) . We therefore wished to confirm a role for early carbohydrate processing and calnexin binding in the ERAD process for cog Tg and cdPC, which cause inherited and acquired ERSDs, respectively (36; 37).
After synthesis, both misfolded glycoproteins were extensively degraded (Figs. 1, 12 ) via a proteasomal mechanism. Confirming the work of Sifers and colleagues (35), we found that KIF, an inhibitor of ER mannosidase I (41), selectively suppressed ERAD for both misfolded glycoproteins (Figs. 3, 9 ). More specifically, the data suggested that cog Tg protected from ERAD failed to undergo trimming from Man 9 to Man 8 (Fig. 4) . KIF treatment did not impair the anterograde traffic of native Tg or PC from the ER (Fig. 5 , and data not shown), nor did it affect the degradation of misfolded Tg or PC that was unglycosylated after tunicamycin treatment (Fig. 10) 2 . However, KIF did appear to impair retrotranslocation of the misfolded glycoproteins to the cytosol, based upon microsomal sedimentation data (Fig. 6 ) and our (unpublished) observations that native and misfolded forms showed no difference in trypsin sensitivity in microsomal protease protection assays. However, we cannot exclude the possibility of a limited degree of retrotranslocation to the cytosol in the presence of lactacystin that is below the detection limits of our assays (23), although we could find no evidence for accumulation of insoluble Tg aggregates (Fig. 7) in cytosolic aggresomes (44) . Suppressed Tg degradation was also observed in DTT treated cells (Fig. 8); together these data suggest that the effects of mannosidase I are not limited to specific protein domains but seem to represent a more general feature in the ERAD process for at least a subset of glycoproteins.
Unlike for α1-antitrypsin, suppression of ERAD with inhibitors of ER mannosidase I occurred efficiently even in cells continuously treated with CAS (Figs. 3, 9 ). Under these conditions the lectin-like binding of calnexin towards monoglucosylated oligosaccharides cannot be initiated (18; 27; 28; 55); moreover, these conditions also interfere with glycoprotein association of calreticulin (56) as well as ER60/ERp57 (57). Thus, while data implicating lectin-like calnexin association has been presented in some cases (13; 35; 58) , an important conclusion from the present study [in conjunction with previous results (18) (19) (20) (21) (22) (23) ] is that a lectin-mediated association of the calnexin/calreticulin-ERp57 complex is not a general requirement for retrotranslocation of misfolded glycoproteins to the ERAD machinery. However, since ER chaperones are likely to be associated in a network (59) and since different ERAD substrates exhibit different patterns of chaperone binding (42) , it is most probable that multiple ER chaperones have the potential to participate in the targeting of different misfolded protein substrates for retrotranslocation and ERAD.
Current reports suggest plasticity in the mechanisms leading to ER targeting for proteolysis. For example, ERAD occurs also for unglycosylated (misfolded) exportable proteins (14) (Fig. 10) .
Additionally, there is one N-linked glycoprotein -the T-cell receptor α-subunit -for which inhibition of mannosidase activity does not significantly suppress the ERAD process (34).
Importantly, complete deglycosylation has been reported as an intermediate stage in ERAD for several misfolded glycoprotein substrates (43; 60-63) based on PNGase activity that may be localized to the cytosol (64) or to the ER (65; 66). Based on these observations it is reasonable to propose plasticity in the ERAD pathway involving the existence of distinct, and perhaps parallel, initial targeting. In this case, a Man 8 GlcNac 2 oligosaccharide structure specific to the "B-isoform" configuration [i.e., such that after mannosidase cleavage, a terminal mannose remains in the α1,3
linkage (41)] may directly or indirectly facilitate protein disposition via one of these routes, and when this is blocked, undegraded intermediates presumably acccumulate until alternate degradative routes prevail. The existence of such alternate routes presumably accounts for the fact that eventual degradation of cog Tg and cdPC is observed even in the presence of KIF. Thus, two alternate hypotheses that need to be tested are: 1) although not absolutely required, mannose recognition and trimming may be an important priming step in the pathway of deglycosylation preceding ERAD; alternatively, 2) the B isoform of Man 8 GlcNac 2 oligosaccharides might facilitate the presentation of misfolded glycoproteins (53) for multi-ubiquitination (6; 22; 23; 34; 67). Either or both of these activities might be associated (physically or kinetically) with retrotranslocation through the Sec61 translocon (58).
With these thoughts in mind, we note that oligosaccharide trimming by ER mannosidase I appears to be a relatively slow step in the processing of cog Tg and cdPC (Figs. 11 and 13 ). We therefore expected that cog Tg might massively accumulate in the ER in the setting of chronic KIF treatment, which could trigger the unfolded protein response (68) . However after 3 d of KIF treatment, cog Tg accumulated only moderately and no clear increase in BiP, GRP94, ERp72, calreticulin, or ER60 was observed (Fig. 14A) . Potentially, alternate routes directing cog Tg to proteasomal degradation could be induced under these conditions (which may be consistent with results of Fig. 14 B, C) . We After a 2h chase, the cell lysates were immunoprecipitated for Tg and some digested further with PNGase F (P) or jack-bean mannosidase (J). The samples were finally analyzed by 4% SDS-PAGE in a long (20 cm) slab gel format to discriminate small mobility differences.
FIG. 5. Mannose-and/or glucose-trimming does not affect the secretion of wild-type (wt) Tg. A;
CHO cells expressing wt Tg were labeled as in Fig. 1 
